Nifty
:
24968.40
Sensex
:
81757.73
-143.05 (-0.57%)
-501.51 (-0.61%)
Nifty
Sensex
:
:
24968.40
81757.73
-143.05 (-0.57%)
-501.51 (-0.61%)

Strides Pharma Science Ltd.

Pharmaceuticals & Drugs - Global

Rating :
74/99

BSE: 532531 | NSE: STAR

NSE BSE
881.80
18-Jul-2025
  • Open
  • High
  • Low
  • Previous Close
  •  894.1
  •  900
  •  864
  •  895.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  418455
  •  367835787.25
  •  956
  •  402.62

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 8,127.83
  • 2.26
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 9,786.66
  • 0.45%
  • 3.19

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 28.30%
  • 3.82%
  • 21.52%
  • FII
  • DII
  • Others
  • 28.32%
  • 11.92%
  • 6.12%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.78
  • 6.60
  • 7.37

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.68
  • 4.94
  • 15.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.60
  • 2.84
  • 132.95

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.95
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.20
  • 2.45
  • 2.69

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.95
  • 16.20
  • 14.02

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
-7.76
390.5
51.9
67.8
P/E Ratio
-113.63
2.26
16.99
13.01
Revenue
4051
4565
5123
5719
EBITDA
743
954
1101
Net Income
-71
3593
479
625
ROA
-1.1
P/B Ratio
2.28
2.70
2.29
ROE
-3.26
17.1
19.1
FCFF
308
491
623
FCFF Yield
3.52
5.62
7.13
Net Debt
2199
BVPS
387.5
326.58
384.36

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
1,190.39
1,043.50
14.08%
1,153.67
1,005.77
14.71%
1,201.11
999.43
20.18%
1,087.50
929.99
16.94%
Expenses
972.52
839.19
15.89%
943.35
863.78
9.21%
965.30
846.30
14.06%
870.52
763.40
14.03%
EBITDA
217.87
204.31
6.64%
210.31
141.99
48.12%
235.81
153.13
53.99%
216.98
166.59
30.25%
EBIDTM
18.30%
19.58%
18.23%
14.12%
19.63%
15.32%
19.95%
17.91%
Other Income
11.98
-13.55
-
5.62
8.75
-35.77%
28.41
35.85
-20.75%
12.72
8.64
47.22%
Interest
50.32
71.10
-29.23%
52.18
69.71
-25.15%
82.15
78.59
4.53%
80.39
76.42
5.19%
Depreciation
48.86
47.94
1.92%
48.42
49.44
-2.06%
50.52
60.10
-15.94%
48.59
59.59
-18.46%
PBT
103.25
63.66
62.19%
112.89
21.52
424.58%
127.67
-114.64
-
96.98
33.25
191.67%
Tax
20.76
12.52
65.81%
23.80
15.74
51.21%
21.20
-7.44
-
16.86
9.68
74.17%
PAT
82.49
51.14
61.30%
89.09
5.78
1,441.35%
106.47
-107.20
-
80.12
23.57
239.92%
PATM
6.93%
4.90%
7.72%
0.57%
8.86%
-10.73%
7.37%
2.53%
EPS
8.92
1.98
350.51%
9.54
5.41
76.34%
10.14
-14.54
-
7.64
-0.77
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
-
4,565.34
3,890.13
3,688.39
3,070.25
3,315.87
2,981.12
3,108.33
3,344.37
3,826.22
2,862.19
Net Sales Growth
-
17.36%
5.47%
20.13%
-7.41%
11.23%
-4.09%
-7.06%
-12.59%
33.68%
 
Cost Of Goods Sold
-
1,979.96
1,749.05
1,626.88
1,502.32
1,332.79
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
Gross Profit
-
2,585.37
2,141.07
2,061.50
1,567.93
1,983.08
1,858.64
2,023.14
1,965.53
2,545.05
1,359.90
GP Margin
-
56.63%
55.04%
55.89%
51.07%
59.81%
62.35%
65.09%
58.77%
66.52%
47.51%
Total Expenditure
-
3,767.56
3,317.89
3,303.09
3,091.76
2,689.06
2,470.90
2,811.65
3,108.66
3,309.30
2,481.62
Power & Fuel Cost
-
58.17
75.13
85.82
71.54
64.58
64.49
54.39
51.33
33.87
77.18
% Of Sales
-
1.27%
1.93%
2.33%
2.33%
1.95%
2.16%
1.75%
1.53%
0.89%
2.70%
Employee Cost
-
862.76
737.05
732.02
646.91
550.15
442.56
329.44
434.05
419.16
357.69
% Of Sales
-
18.90%
18.95%
19.85%
21.07%
16.59%
14.85%
10.60%
12.98%
10.95%
12.50%
Manufacturing Exp.
-
311.98
299.81
259.45
255.52
237.94
210.79
150.98
115.97
137.47
119.23
% Of Sales
-
6.83%
7.71%
7.03%
8.32%
7.18%
7.07%
4.86%
3.47%
3.59%
4.17%
General & Admin Exp.
-
221.56
198.06
232.21
223.67
191.73
191.89
150.10
194.38
172.63
198.71
% Of Sales
-
4.85%
5.09%
6.30%
7.29%
5.78%
6.44%
4.83%
5.81%
4.51%
6.94%
Selling & Distn. Exp.
-
298.20
215.03
263.65
331.30
223.22
137.07
111.22
208.85
161.12
129.57
% Of Sales
-
6.53%
5.53%
7.15%
10.79%
6.73%
4.60%
3.58%
6.24%
4.21%
4.53%
Miscellaneous Exp.
-
34.93
43.76
103.06
60.51
88.65
301.61
930.33
725.25
1,103.88
129.57
% Of Sales
-
0.77%
1.12%
2.79%
1.97%
2.67%
10.12%
29.93%
21.69%
28.85%
3.39%
EBITDA
-
797.78
572.24
385.30
-21.51
626.81
510.22
296.68
235.71
516.92
380.57
EBITDA Margin
-
17.47%
14.71%
10.45%
-0.70%
18.90%
17.12%
9.54%
7.05%
13.51%
13.30%
Other Income
-
63.76
49.85
135.22
133.40
59.44
66.70
322.90
920.64
398.08
102.37
Interest
-
248.85
280.22
261.14
176.74
150.06
155.72
79.29
196.24
183.10
168.17
Depreciation
-
192.26
213.64
243.25
233.01
206.29
187.79
171.85
193.93
198.69
131.25
PBT
-
420.42
128.22
16.11
-297.88
329.90
233.42
368.44
766.17
533.20
183.50
Tax
-
77.52
29.11
-55.30
-178.26
31.65
17.91
14.49
21.41
51.19
42.45
Tax Rate
-
15.98%
-47.86%
6010.87%
32.91%
8.48%
11.50%
3.71%
2.96%
10.30%
29.87%
PAT
-
405.34
-120.20
-221.20
-460.21
352.32
143.62
370.31
681.31
399.38
113.21
PAT before Minority Interest
-
409.40
-143.90
-230.90
-474.25
341.61
137.82
375.57
701.18
445.58
99.68
Minority Interest
-
-4.06
23.70
9.70
14.04
10.71
5.80
-5.26
-19.87
-46.20
13.53
PAT Margin
-
8.88%
-3.09%
-6.00%
-14.99%
10.63%
4.82%
11.91%
20.37%
10.44%
3.96%
PAT Growth
-
-
-
-
-
145.31%
-61.22%
-45.65%
70.59%
252.78%
 
EPS
-
43.96
-13.04
-23.99
-49.91
38.21
15.58
40.16
73.89
43.32
12.28

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
2,551.83
2,125.57
2,212.26
2,359.23
2,776.66
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
Share Capital
92.16
91.90
90.30
89.79
89.68
89.56
89.55
89.50
89.42
89.35
Total Reserves
2,459.16
2,030.57
2,102.54
2,266.99
2,682.26
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
Non-Current Liabilities
601.61
621.44
1,210.30
965.72
1,264.45
813.65
2,342.88
2,067.29
2,048.67
2,760.03
Secured Loans
558.47
618.40
1,040.81
744.86
873.43
601.79
1,806.45
1,551.09
1,622.87
2,614.88
Unsecured Loans
12.78
53.10
98.98
90.77
9.15
2.12
0.06
0.23
14.84
12.13
Long Term Provisions
113.94
91.63
73.42
64.28
246.50
63.95
52.24
16.55
25.19
14.45
Current Liabilities
2,591.52
2,879.26
2,990.20
3,411.68
2,738.35
2,544.86
2,662.24
1,899.30
3,103.87
1,891.98
Trade Payables
1,032.50
851.59
982.34
1,071.52
1,134.20
797.75
888.99
712.07
774.09
775.40
Other Current Liabilities
307.41
341.57
527.89
697.18
421.00
354.49
248.12
129.98
819.08
347.93
Short Term Borrowings
1,136.36
1,574.15
1,330.76
1,496.53
1,023.84
1,228.78
1,339.02
944.39
1,393.96
700.48
Short Term Provisions
115.25
111.94
149.20
146.43
159.31
163.84
186.11
112.86
116.73
68.19
Total Liabilities
5,779.59
5,572.41
6,373.38
6,760.72
6,816.80
5,953.17
7,806.77
6,584.90
8,034.86
7,360.09
Net Block
1,888.12
1,853.18
2,298.42
2,333.45
2,151.13
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
Gross Block
2,897.25
2,873.18
3,324.82
3,231.69
2,841.28
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
Accumulated Depreciation
1,009.14
1,020.00
1,026.40
898.24
690.15
508.53
478.92
326.03
277.09
146.75
Non Current Assets
2,680.68
2,603.41
3,130.03
3,398.88
3,999.57
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
Capital Work in Progress
206.76
161.89
150.98
291.08
447.37
412.95
453.03
620.29
780.18
814.88
Non Current Investment
339.71
196.93
438.96
540.34
666.23
503.24
494.34
350.08
315.66
127.19
Long Term Loans & Adv.
140.19
256.13
217.18
210.58
185.80
210.82
223.69
197.22
222.56
201.83
Other Non Current Assets
94.73
123.38
11.91
10.26
549.04
428.19
16.86
30.72
15.62
22.62
Current Assets
3,098.91
2,969.00
3,135.25
3,361.83
2,817.23
2,372.11
3,048.72
2,483.59
3,791.82
3,514.89
Current Investments
69.50
105.76
50.84
0.00
99.41
118.97
284.75
311.48
1,279.54
1,213.76
Inventories
1,277.57
1,126.24
1,146.51
1,173.80
1,200.70
782.54
874.16
552.02
732.80
613.14
Sundry Debtors
1,202.94
1,141.87
1,299.40
1,207.30
1,110.59
931.69
987.18
882.18
995.91
1,032.97
Cash & Bank
136.78
191.17
315.96
187.35
179.76
237.10
516.65
303.33
329.48
311.59
Other Current Assets
412.12
228.99
169.21
647.90
226.76
301.81
385.98
434.59
454.09
343.44
Short Term Loans & Adv.
135.92
174.97
153.34
145.49
128.54
218.24
249.11
295.75
244.39
97.54
Net Current Assets
507.39
89.74
145.05
-49.84
78.89
-172.75
386.48
584.29
687.95
1,622.91
Total Assets
5,779.59
5,572.41
6,265.28
6,760.71
6,816.80
5,953.16
7,806.77
6,584.90
8,034.87
7,360.09

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
684.37
701.07
44.41
-257.81
481.44
204.79
60.05
187.07
288.14
73.25
PBT
3,675.03
-62.72
-267.63
-652.51
289.38
48.51
344.37
705.80
497.14
146.44
Adjustment
-2,893.97
818.27
682.19
582.27
363.31
527.49
94.59
-274.51
190.92
345.56
Changes in Working Capital
-163.72
-78.73
-457.80
-189.90
-328.05
-326.23
-323.14
-190.66
-341.30
-341.71
Cash after chg. in Working capital
617.34
676.82
-43.23
-260.14
324.64
249.76
115.82
240.63
346.76
150.29
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
67.04
24.25
87.64
2.33
156.80
-44.98
-55.76
-53.56
-58.62
-77.04
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-89.69
-150.25
302.47
-118.73
-520.82
1,306.16
-148.49
582.59
-686.69
-2,224.83
Net Fixed Assets
-32.00
-315.30
-54.00
-61.59
-86.75
-167.06
-48.49
677.20
-236.66
-535.93
Net Investments
515.90
128.18
-92.01
62.72
-219.57
-17.15
-383.09
747.64
-143.27
-1,478.58
Others
-573.59
36.87
448.48
-119.86
-214.50
1,490.37
283.09
-842.25
-306.76
-210.32
Cash from Financing Activity
-642.58
-693.32
-213.92
421.32
-15.80
-1,709.45
194.27
-1,015.69
338.21
2,943.94
Net Cash Inflow / Outflow
-47.90
-142.51
132.96
44.77
-55.18
-198.50
105.83
-246.03
-60.33
792.35
Opening Cash & Equivalents
161.02
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.91
Closing Cash & Equivalent
112.56
161.02
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
276.83
230.95
242.83
262.48
309.09
281.55
294.94
274.26
306.41
296.83
ROA
7.21%
-2.41%
-3.52%
-6.99%
5.35%
2.00%
5.22%
9.59%
5.79%
2.03%
ROE
17.52%
-6.67%
-10.15%
-18.49%
12.91%
5.34%
14.74%
27.00%
16.53%
5.25%
ROCE
16.56%
3.47%
-0.49%
-9.49%
11.17%
6.01%
8.65%
16.07%
10.75%
7.54%
Fixed Asset Turnover
2.46
1.96
1.91
1.75
2.04
1.50
1.17
1.04
1.27
1.47
Receivable days
60.35
73.17
73.25
79.41
68.09
70.88
79.95
102.49
96.77
90.73
Inventory Days
61.86
68.12
67.80
81.35
66.13
61.20
61.00
70.11
64.20
52.34
Payable days
173.66
191.36
230.40
267.95
264.54
138.58
146.59
116.23
117.33
75.51
Cash Conversion Cycle
-51.45
-50.07
-89.35
-107.20
-130.32
-6.50
-5.64
56.37
43.64
67.55
Total Debt/Equity
0.70
1.14
1.27
1.18
0.76
0.78
1.22
1.03
1.35
1.34
Interest Cover
2.96
0.59
-0.10
-2.69
3.49
2.00
5.92
4.68
3.71
1.85

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Strides Pharma Science’s arm acquires identified ANDAs from Nostrum Laboratories, Inc, USA
    30th Apr 2025, 11:23 AM

    Two (out of the Four) ANDAs acquired are commercial products and is expected to be launched within 12 months

    Read More
  • Strides Pharma Science's arm incorporates wholly owned subsidiary
    11th Apr 2025, 15:00 PM

    Pivot Path shall focus on life sciences and manufacturing solutions with deep domain knowledge and cutting-edge technology capabilities

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.